Plasma substitution effects of a new hydroxyethyl starch HES 130/0.4 compared with HES 200/0.5 during and after extended acute normovolaemic haemodilution

British Journal of Anaesthesia

Volumn 91, Issue 2, 2003, Pages 196-202

  Ickx, B E ^a   Bepperling, F ^b   Melot, C ^a   Schulman, C ^a   Van der Linden, Philippe J ^c  

^a ERASME HOSPITAL   (Belgium)

^b Clinical Research Department   (Germany)

^c Centre Hospitalier Universitaire de Charleroi   (Belgium)

Author keywords

Blood, colloid substitution; Blood, haemodilution; Cardiovascular system; Complications, acute anaemia; Oxygen, transport

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEMOGLOBIN; HETASTARCH; PLASMA SUBSTITUTE;

ABDOMINAL SURGERY; ADULT; AGED; ANESTHESIA INDUCTION; ARTICLE; BLEEDING; BLOOD TRANSFUSION; BLOOD VOLUME; CLINICAL ARTICLE; CLINICAL TRIAL; COLLOID; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYSTALLOID; DEEP VEIN THROMBOSIS; DRUG HYPERSENSITIVITY; ERYTHROCYTE TRANSFUSION; FEMALE; HEART INDEX; HEART INFARCTION; HEART OUTPUT; HEART RATE; HEART VENTRICLE FILLING; HEMODILUTION; HEMODYNAMICS; HUMAN; MAJOR SURGERY; MALE; MEAN ARTERIAL PRESSURE; PLASMA VOLUME; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT CONTRAINDICATION;

EID: 0041700044     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/aeg159     Document Type: Article

References (18)

1. Mishler IV JM. Synthetic plasma volume expanders - their pharmacology, safety and clinical efficacy. Clin Haemotol 1984; 13: 75-92
2. Treib J, Baron JF, Grauer MT, Strauss RG. An international view of hydroxyethyl starches. Intensive Care Med 1999; 25: 258-68
3. Waitzinger J, Bepperling F, Pabst G, Opitz J, Müller M, Baron JF. Pharmacokinetics and tolerability of a new hydroxyethyl starch (HES) specification (HES 130/0.4) after single-dose infusion of 6% or 10% solutions in healthy volunteers. Clin Drug Invest 1998; 16: 151-60
4. Jungheinrich C, Scharpf R, Wargenau M, Bepperling F, Baron JF. The pharmacokinetics and tolerability of an intravenous infusion of the new hydroxyethyl starch 130/0.4 6% in mild-to-severe renal impairment. Anesth Analg 2002; 95: 544-51
5. Waitzinger J, Bepperling F, Pabst G, Opitz J, Fackelmeyer A, Boldt J. Effect of a new hydroxyethyl starch (HES) specification [HES (130/0.4)] on blood and plasma volumes after bleeding in 12 healthy male volunteers. Clin Drug Invest 1999; 17: 119-25
6. Kasper SM, Stromich A, Kampe S, Radbruch L. Evaluation of a new hydroxyethyl starch solution (HES 130/0.4) in patients undergoing preoperative autologous blood donation. J Clin Anesth 2001; 13: 486-90
7. Weiskopf RB. Hemodilution and candles. Anesthesiology 2002; 97: 773-5
8. Matot I, Scheinin O, Jurim O, Eid A. Effectiveness of acute normovolemic hemodilution to minimize allogeneic blood transfusion in major liver resections. Anesthesiology 2002; 97: 794-800
9. Daper A, Parquier J-N, Preiser J-C, Contempre B, Vincent J-L. Timing of cardiac output measurements during mechanical ventilation. Acute Care 1989; 12: 113-16
10. Viitanen A, Salmenpera M, Heinonen J. Right ventricular response to hypercarbia after cardiac surgery. Anesthesiology 1991; 73: 393-400
11. Weidler B, von Bormann B, Sommermeyer K, Lohmann E, Peil J, Hempelmann G. Pharmakokinetische Merkmale als Kriterien für den klinischen Einsatz von Hydroxyethylstärke. Drug Res 1991; 41: 494-8
12. Boldt J, Lehmann A, Römpert R, Haisch G, Isgro F. Volume therapy with a new hydroxyethyl starch solution in cardiac surgical patients before cardiopulmonary bypass. J Cardiothorac Anesth 2000; 14: 264-8
13. Ickx B, Rigolet M, Van der Linden P. Cardiovascular and metabolic response to acute normovolemic anemia: effects of anesthesia. Anesthesiology 2000; 93: 1011-16
14. Langeron O, Doelberg M, Eng-Than A, Bonnet F, Capdevila X, Coriat P. Voluven®, a lower substituted novel hydroxyethylstarch (HES 130/0.4), causes fewer effects on coagulation in major orthopedic surgery than HES 200/0.5. Anesth Analg 2001; 92: 855-62
15. Huet RCG, Siemons AW, Baus D, et al. A novel hydroxyethylstarch (Voluven®) for effective perioperative plasma volume substitution in cardiac surgery. Can J Anaesth 2000; 47: 1207-15
16. Köhler H, Zschiedrich H, Linfante A, Appel F, Pitz H, Clasen R. Die Elimination von Hydroxyethylstärche 200/0.5, Dextran 40 und Oxypolygelatine. Klin Wochenschr 1982; 60: 293-301
17. Boldt J, Haisch G, Suttner S, Kumle B, Schellhaass A. Effects of a new modified, balanced hydroxyethyl starch preparation (Hextend®) on measures of coagulation. Br J Anaesth 2002; 89: 722-8
18. Yacobi A, Stoll RG, Sum CY, Lai CM, Gupta SD, Hulse JD. Pharmacokinetics of hydroxyethyl starch in normal subjects. J Clin Pharmacol 1982; 22: 206-12